Humbrecht C, Kientz D, Gachet C
Établissement français du sang grand est, 85-87, boulevard Lobau, 54064 Nancy cedex, France.
Établissement français du sang grand est, 85-87, boulevard Lobau, 54064 Nancy cedex, France.
Transfus Clin Biol. 2018 Sep;25(3):151-164. doi: 10.1016/j.tracli.2018.06.004. Epub 2018 Jul 20.
Since the late sixties, platelet concentrates are transfused to patients presenting with severe thrombocytopenia, platelet function defects, injuries, or undergoing surgery, to prevent the risk of bleeding or to treat actual hemorrhage. Current practices differ according to the country or even in different hospitals and teams. Although crucial advances have been made during the last decades, questions and debates still arise about the right doses to transfuse, the use of prophylactic or therapeutic strategies, the nature and quality of PC, the storage conditions, the monitoring of transfusion efficacy and the microbiological and immunological safety of platelet transfusion. Finally, new challenges are emerging with potential new platelet products, including cold stored or in vitro produced platelets. The most debated of these points are reviewed.
自六十年代末以来,血小板浓缩物被输注给患有严重血小板减少症、血小板功能缺陷、受伤或正在接受手术的患者,以预防出血风险或治疗实际出血情况。目前的做法因国家而异,甚至在不同医院和团队中也有所不同。尽管在过去几十年里取得了重大进展,但关于输注的合适剂量、预防性或治疗性策略的使用、血小板浓缩物的性质和质量、储存条件、输血疗效监测以及血小板输血的微生物和免疫安全性等问题和争论仍然存在。最后,随着潜在的新血小板产品的出现,包括冷藏或体外生产的血小板,新的挑战也在浮现。本文对这些最具争议的要点进行了综述。